腹腔镜肝门部胆管癌根治性切除操作流程专家建议

2019-08-30 中华外科杂志编辑委员会 中华外科杂志.2019.57(8):561-567.

根治性切除是目前肝门部胆管癌唯一治愈性的治疗手段。随着腹腔镜器械的不断更新和技术的不断提高,腹腔镜肝门部胆管癌根治性切除在国内已逐步开展,其可行性和安全性得到国内部分同行的认可。为规范临床诊疗行为,保障患者得到安全、规范的治疗及改善预后,腹腔镜肝门部胆管癌根治切除术操作规范专家组和中华外科杂志编辑部组织国内相关专家,遵循肝门部胆管癌治疗原则和腹腔镜操作相应的技术规范,制定腹腔镜肝门部胆管癌根治性切

中文标题:

腹腔镜肝门部胆管癌根治性切除操作流程专家建议

发布日期:

2019-08-30

简要介绍:

根治性切除是目前肝门部胆管癌唯一治愈性的治疗手段。随着腹腔镜器械的不断更新和技术的不断提高,腹腔镜肝门部胆管癌根治性切除在国内已逐步开展,其可行性和安全性得到国内部分同行的认可。为规范临床诊疗行为,保障患者得到安全、规范的治疗及改善预后,腹腔镜肝门部胆管癌根治切除术操作规范专家组和中华外科杂志编辑部组织国内相关专家,遵循肝门部胆管癌治疗原则和腹腔镜操作相应的技术规范,制定腹腔镜肝门部胆管癌根治性切除操作流程专家建议,便于临床借鉴及规范化应用。

 

拓展威廉亚洲博彩公司 :胆管癌相关威廉亚洲博彩公司 :

相关资料下载:
[AttachmentFileName(sort=100, fileName=腹腔镜肝门部胆管癌根治性切除操作流程专家建议)] GetToolGuiderByIdResponse(projectId=1, id=519fc1c001e995bb, title=腹腔镜肝门部胆管癌根治性切除操作流程专家建议, enTitle=, guiderFrom=中华外科杂志.2019.57(8):561-567., authorId=null, author=, summary=根治性切除是目前肝门部胆管癌唯一治愈性的治疗手段。随着腹腔镜器械的不断更新和技术的不断提高,腹腔镜肝门部胆管癌根治性切除在国内已逐步开展,其可行性和安全性得到国内部分同行的认可。为规范临床诊疗行为,保障患者得到安全、规范的治疗及改善预后,腹腔镜肝门部胆管癌根治切除术操作规范专家组和中华外科杂志编辑部组织国内相关专家,遵循肝门部胆管癌治疗原则和腹腔镜操作相应的技术规范,制定腹腔镜肝门部胆管癌根治性切, cover=, journalId=null, articlesId=null, associationId=607, associationName=中华外科杂志编辑委员会, associationIntro=null, copyright=0, guiderPublishedTime=Fri Aug 30 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>根治性切除是目前肝门部胆管癌唯一治愈性的治疗手段。随着腹腔镜器械的不断更新和技术的不断提高,腹腔镜肝门部胆管癌根治性切除在国内已逐步开展,其可行性和安全性得到国内部分同行的认可。为规范临床诊疗行为,保障患者得到安全、规范的治疗及改善预后,腹腔镜肝门部胆管癌根治切除术操作规范专家组和中华外科杂志编辑部组织国内相关专家,遵循肝门部胆管癌治疗原则和腹腔镜操作相应的技术规范,制定腹腔镜肝门部胆管癌根治性切除操作流程专家建议,便于临床借鉴及规范化应用。 </P> <P> </P>拓展威廉亚洲博彩公司 :<strong>与<font color=red>胆管癌</font>相关威廉亚洲博彩公司 :</strong><br><ul><li><a href="//www.nyrain.com/guideline/show_article.do?id=c62b71c001e67863" title="2019 ASCO临床实践威廉亚洲博彩公司 :已切除胆管癌的辅助治疗" target=_blank>2019 ASCO临床实践威廉亚洲博彩公司 :已切除胆管癌的辅助治疗</a></li> <li><a href="//www.nyrain.com/guideline/show_article.do?id=fe56a1c001290643" title="2016 ESMO临床诊疗威廉亚洲博彩公司 :胆管癌的诊断、治疗与随访" target=_blank>2016 ESMO临床诊疗威廉亚洲博彩公司 :胆管癌的诊断、治疗与随访</a></li> <li><a href="//www.nyrain.com/guideline/show_article.do?id=077151c00120a31e" title="AHPBA专家共识声明:肝内胆管癌(2015年)" target=_blank>AHPBA专家共识声明:肝内胆管癌(2015年)</a></li> <li><a href="//www.nyrain.com/guideline/show_article.do?id=3b4301c00120a2ca" title="AHPBA专家共识声明:肝门部胆管癌(2015年)" target=_blank>AHPBA专家共识声明:肝门部胆管癌(2015年)</a></li> <li><a href="//www.nyrain.com/guideline/show_article.do?id=819d91c001203ecc" title="肝门部胆管癌诊断和治疗威廉亚洲博彩公司 (2013版)的解读与思考" target=_blank>肝门部胆管癌诊断和治疗威廉亚洲博彩公司 (2013版)的解读与思考</a></li> 更多信息请点击:<a href="//www.nyrain.com/guideline/list.do?q=%E8%83%86%E7%AE%A1%E7%99%8C" target=_blank>有关胆管癌更多威廉亚洲博彩公司 </a></ul>, tagList=[TagDto(tagId=94978, tagName=腹腔镜肝门部胆管癌根治性切除术), TagDto(tagId=94979, tagName=操作流程)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=91, categoryName=肝胆胰外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4659, appHits=256, showAppHits=5, pcHits=3080, showPcHits=2367, likes=63, shares=16, comments=4, approvalStatus=1, publishedTime=Mon Sep 30 13:23:31 CST 2019, publishedTimeString=2019-08-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Sep 30 13:23:31 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 15:10:24 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=腹腔镜肝门部胆管癌根治性切除操作流程专家建议)])
腹腔镜肝门部胆管癌根治性切除操作流程专家建议
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1228241, encodeId=f36912282414f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d25091682, createdName=145d4c03m99暂无昵称, createdTime=Thu Jun 23 16:33:23 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073601, encodeId=9abf10e360111, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/28/c61b7a81f8df2f03fc4d3ec8aa866af5.jpg, createdBy=ee2b2577154, createdName=陈小刀, createdTime=Wed Nov 24 20:01:01 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958808, encodeId=6dd895880885, content=受教了,精品, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92455482358, createdName=ms9000001980664381, createdTime=Tue Apr 20 18:06:04 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
    2022-06-23 145d4c03m99暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1228241, encodeId=f36912282414f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d25091682, createdName=145d4c03m99暂无昵称, createdTime=Thu Jun 23 16:33:23 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073601, encodeId=9abf10e360111, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/28/c61b7a81f8df2f03fc4d3ec8aa866af5.jpg, createdBy=ee2b2577154, createdName=陈小刀, createdTime=Wed Nov 24 20:01:01 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958808, encodeId=6dd895880885, content=受教了,精品, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92455482358, createdName=ms9000001980664381, createdTime=Tue Apr 20 18:06:04 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
    2021-11-24 陈小刀

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1228241, encodeId=f36912282414f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d25091682, createdName=145d4c03m99暂无昵称, createdTime=Thu Jun 23 16:33:23 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073601, encodeId=9abf10e360111, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/28/c61b7a81f8df2f03fc4d3ec8aa866af5.jpg, createdBy=ee2b2577154, createdName=陈小刀, createdTime=Wed Nov 24 20:01:01 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958808, encodeId=6dd895880885, content=受教了,精品, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92455482358, createdName=ms9000001980664381, createdTime=Tue Apr 20 18:06:04 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
    2021-04-20 ms9000001980664381

    受教了,精品

    0